{
  "nctId": "NCT05222139",
  "briefTitle": "Monitoring COVID-19 Vaccination Response in Fragile Populations",
  "officialTitle": "\"Multicenter Observational Study to Assess the Incidence and Features of COVID-19 and the Response to COVID-19 Vaccination in Fragile Patients\"",
  "protocolDocument": {
    "nctId": "NCT05222139",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-09-28",
    "uploadDate": "2021-11-05T07:02",
    "size": 1747688,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05222139/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 8894,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-05-24",
    "completionDate": "2024-11-30",
    "primaryCompletionDate": "2023-07-16",
    "firstSubmitDate": "2021-11-08",
    "firstPostDate": "2022-02-03"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Any age\n* Any comorbidity\n* Person (or attorney or deputy who has been authorized to make the decision for patients who lack capacity) consent to participate or appropriate local waiver of consent.\n\nExclusion Criteria:\n\n* Patients did not agree to participate",
    "healthyVolunteers": false,
    "sex": "ALL",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Early immune response to COVID-19 vaccine patients",
        "description": "To investigate the early immune response to COVID-19 vaccine in fragile patients assessing the levels of antibodies against Spike antigens and the patterns of cellular immune response",
        "timeFrame": "3 ± 1 month after vaccination onset"
      },
      {
        "measure": "Late immune response to COVID-19 vaccine",
        "description": "To investigate the late immune response to COVID-19 vaccine in fragile patients assessing the levels of antibodies against Spike antigens and the patterns of cellular immune response",
        "timeFrame": "12 ± 3 months after vaccination onset"
      },
      {
        "measure": "Rate of COVID-19 breakthrough infections",
        "description": "To investigate the rate of COVID-19 breakthrough infections in fragile patients within 1 year after vaccination onset",
        "timeFrame": "within 1 year after vaccination onset"
      },
      {
        "measure": "Rate of hospital admission for COVID-19 breakthrough infections condition and its impact on the outcome in fragile patients",
        "description": "To investigate the rate of hospital admission for COVID-19 breakthrough infections in fragile patients",
        "timeFrame": "within 1 year after vaccination onset"
      },
      {
        "measure": "Rate of death for COVID-19 breakthrough infections patients",
        "description": "To investigate the rate of death for COVID-19 breakthrough infections in fragile patients",
        "timeFrame": "within 1 year after vaccination onset"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 5,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 69,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:37.165Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}